Cambridge Cog Regulatory News (COG)

30 January 2024

Cambridge Cognition Holdings plc

("Cambridge Cognition" or the "Company")

Board appointments

Cambridge Cognition Holdings plc (AIM: COG), which develops and markets digital solutions to assess brain health, is pleased to announce the appointment of Stuart Gall and Philip Rodgers ("Nick") as independent non-executive Directors of the Company, both with effect from 1 February 2024. 

As announced in the Trading Update this morning, the Company has seen revenue growth of 7% in 2023 and an adjusted operating profit in the second half in a difficult economic environment and is positioned to deliver further growth in the future. The appointments will strengthen the Board to support these growth plans by adding additional commercial, investor relations and financial expertise. The additions to the Board take the number of non-executive directors to five; providing strengthened governance and succession for possible future rotation of Board members.

Stuart Gall is CEO of Intelligent Ultrasound, an AIM-listed medical imaging company providing one of the world's leading 'classroom to clinic' ultrasound technologies. Previous appointments include joint founder and executive director of Fusion IP plc, an AIM listed university IP commercialisation company, before its purchase by IP Group plc for £103 million in 2014. Stuart has over 30 years' experience in both small company start-ups and public companies and previously worked at British Airways plc, The Promotions Partnership Limited, Anvil Limited and Toad plc (now Journeo plc).

Nick Rodgers is currently Chair of SEHTA, one of the largest health technology membership and networking organisations in the UK supporting businesses in the health technology sector. Until 2023 Nick was Chair of Destiny Pharma plc, a developer of novel anti-infective products and chair of ZPN Energy Limited, a developer of battery storage technologies and systems for the electric vehicle market. Previously, until 2016, Nick was chairman of Oxford BioMedica plc, a pioneer of gene and cell therapy and a leader in lentiviral vector research, development and bioprocessing.

Dr Steven Powell, Chairman of Cambridge Cognition, commented:

"On behalf of the Board, I am delighted to welcome Stuart and Nick to Cambridge Cognition. Their broad expertise and deep industry experience in the healthcare and technology sectors will be extremely valuable in the next stage of Cambridge Cognition's development now that we have integrated the two acquisitions made in 2022/23, which strengthen the Company's product offering and cement its leading market position. We look forward to benefitting from their insights as the Board continues to lead Cambridge Cognition to profitability and accelerate and execute the Company's growth plans."

Further information:

The following details in relation to the appointments of Stuart Gall and Nick Rodgers as directors of the Company are disclosed in accordance with AIM Rule 17 and Schedule 2(g) of the AIM Rules for companies:

Stuart Arthur Gall (aged 61 years) holds or has held the following directorships or partnerships in the last five years:

Stuart was also a director of Abcellute Limited and Abcellute Tissue Bank Limited at the time that both companies entered into a creditors liquidation on 10 October 2012. Abcellute Limited was subsequently dissolved on 17 September 2016 and Abcellute Tissue Bank Limited was dissolved on 10 March 2016.

Philip Nicholas 'Nick' Rodgers (aged 65 years) holds or has held the following directorships or partnerships in the last five years:

Productiv Limited, a company which Nick Rodgers is a director of, entered into a creditors voluntary liquidation on 21 November 2022. The Company is currently still in liquidation.

Save as disclosed above, there is no further information to be disclosed in relation to appointments of Stuart Gall or Nick Rodgers pursuant to AIM Rule 17 or Schedule Two, paragraph (g) of the AIM Rules for Companies.

The information contained within this announcement is deemed by the Company to constitute inside information stipulated under the Market Abuse Regulation (EU) No. 596/2014 as it forms part of UK domestic law by virtue of the European Union (Withdrawal) Act 2018. Upon the publication of this announcement via the Regulatory Information Service, this inside information is now considered to be in the public domain.

Enquiries

Notes to Editors

About Cambridge Cognition

Cambridge Cognition is a technology company developing digital health products to better understand, detect and treat conditions affecting brain health. The Company's software products assess cognitive health in patients worldwide to improve clinical trial outcomes, identify and stratify patients early and improve global efficiency in pharmaceutical and healthcare industries.

For further information visit www.cambridgecognition.com